TY  - GEN
AU  - Pratz,Keith W
AU  - Rudek,Michelle A
AU  - Gojo,Ivana
AU  - Litzow,Mark R
AU  - McDevitt,Michael A
AU  - Ji,Jiuping
AU  - Karnitz,Larry M
AU  - Herman,James G
AU  - Kinders,Robert J
AU  - Smith,B Douglas
AU  - Gore,Steven D
AU  - Carraway,Hetty E
AU  - Showel,Margaret M
AU  - Gladstone,Douglas E
AU  - Levis,Mark J
AU  - Tsai,Hua-Ling
AU  - Rosner,Gary
AU  - Chen,Alice
AU  - Kaufmann,Scott H
AU  - Karp,Judith E
TI  - A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
SN  - 1557-3265
PY  - 2018///0213
KW  - Adult
KW  - Aged
KW  - Benzimidazoles
KW  - administration & dosage
KW  - Carboplatin
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - pathology
KW  - Fanconi Anemia Complementation Group D2 Protein
KW  - genetics
KW  - Female
KW  - Humans
KW  - Leukemia, Biphenotypic, Acute
KW  - drug therapy
KW  - Leukemia, Myelomonocytic, Chronic
KW  - Male
KW  - Middle Aged
KW  - Myeloproliferative Disorders
KW  - Poly (ADP-Ribose) Polymerase-1
KW  - antagonists & inhibitors
KW  - Topotecan
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1158/1078-0432.CCR-16-1274
ER  -